Addex Therapeutics: Creating Novel Small Molecule Drugs for Patients with CNS Diseases
Addex Therapeutics, a Geneva-based biotech developing novel oral small molecule drugs for CNS diseases like Parkinson’s and Alzheimer’s, overcame challenges of outdated data management and complex R&D workflows by implementing the Dotmatics platform, which modernized their data handling, streamlined analysis, and significantly saved scientists’ time, thereby accelerating innovation.
Addex Therapeutics, a biotech headquartered in Geneva, Switzerland, is developing novel, orally available small molecule drugs to address the unmet needs of patients with neurological disorders, such as Parkinson’s, epilepsy, Alzheimer’s, PTSD, depression, neurodegenerative conditions, and other central nervous system (CNS) diseases.
In order to quickly deliver such novel treatment options to patients with CNS diseases, the R&D teams at Addex must be nimble, data-driven, and collaborative. However, this can be challenging when facing complex workflows, huge volumes and varieties of R&D data, and occasional staff departures.
Challenge: Accelerate Innovation via Better R&D Data Management
- Outdated and Unsupported Platform
- Poor Data Management
- Time Wasted Analyzing Data
Solution: Centralizing and Analyzing Data with Dotmatics Platform
- Modernized Platform
- Easy and Manageable Data Flows
- Substantial Time Savings
"One of the biggest, unexpected consequences we’ve seen from integrating Dotmatics is that it saves scientists hours of time spent in analyzing data compared to our previous solution."
— Eric Gaillard, Head of IT and Facility
Related
Early Stage Biotech Customer Stories
Early stage biotech companies like EpiChem, Red X, and ADDEX Therapeutics have successfully transformed their workflows with Dotmatics by overcoming data silos, accelerating analysis, centralizing data access, and enabling scientists to save significant time—up to 50%—on data analysis to focus more on experiments.
Discover Dotmatics: London
The Discover Dotmatics event on October 3rd, 2024, at The Ivy Asia St Pauls in London offers an afternoon of expert presentations on the latest Dotmatics platform updates and Dotmatics Luma, including a talk by Abzena, followed by networking with canapés and drinks from 2:00pm to 5:00pm.
About Dotmatics
Dotmatics is a science-driven company with a mission to build the world’s most powerful scientific R&D platform by uniting best-in-class software applications into a flexible, data-driven ecosystem used by over 2 million scientists worldwide, enabling collaboration, automation, and analysis to accelerate innovation and address global challenges in health, environment, and safety.
Dotmatics at Future Labs, Automation & Technology 2024
Dotmatics will exhibit and host a round table discussion titled "The Data Driven Lab: From Collection to Actionable Insights," led by VP Alister Campbell, at the Future Labs, Automation & Technology 2024 event on December 3, 2024, at the Millennium Gloucester Hotel in London, focusing on integrating data collection and analysis for real-time lab decision-making.
Arkema Selects Dotmatics for R&D Digitalization Project
Arkema has selected Dotmatics to implement a unified electronic laboratory notebook (ELN) across its French research sites, involving 800 users over five years, to digitalize and secure diverse R&D workflows, enhance data access and continuity, accelerate chemical and material innovation through advanced analytics and AI, and facilitate internal and external collaboration.
Simplify your laboratory workflow management with Dotmatics
Dotmatics offers a unified scientific R&D platform that streamlines laboratory workflow management by integrating various scientific applications, automating data extraction, cleaning, and harmonization into FAIR formats, thereby reducing manual data handling, enhancing collaboration, and accelerating the R&D cycle to help life sciences organizations bring new therapies to market faster.